Safety and Tolerability of Intravenous Administration of ICVB-1042
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Julie Maltzman, MD
IconOVir Bio
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- California Cancer Associates
San Marcos, California, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Nyu Langone Health, Perlmutter Cancer Center
New York, New York, United States
- University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Carolina Biooncology
Huntersville, North Carolina, United States
- University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Next Oncology, Dallas
Irving, Texas, United States
- Next Oncology, San Antonio
San Antonio, Texas, United States
- Next Oncology, Virginia
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jun 2023
- Primary completion
- 11 Dec 2024
- Completion
- 20 Dec 2024
- Last update posted
- 8 Apr 2025
- Registered enrollment
- 17
- Registry id
- NCT05904236
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.